文献速递冠心病血脂与心血管预防

慢性肾病合并慢性冠脉综合征患者的白介素6与心血管结局

Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome.
PubMed 文献 · JAMA Cardiol · 2021-01-01

按基线IL-6水平(≥2.0 vs <2.0 ng/L)及eGFR分层分析,发现IL-6升高与主要不良心血管事件(MACE)风险增加相关,且在各肾功能分层中均独立相关。

要点

  • 慢性冠脉综合征患者中,IL-6≥2.0 ng/L与MACE风险增加相关。
  • IL-6与MACE的关联在正常、轻度及中重度肾功能减退患者中均存在。
  • IL-6联合CKD分期可能有助于筛选抗炎治疗人群。

核心结论

  • 在慢性冠脉综合征患者中,IL-6水平升高与各CKD分层下MACE风险增加相关。
  • IL-6和CKD分期可能有助于识别适合抗炎治疗的患者。

研究设计与样本

  • 多中心队列研究,为STABILITY试验的事后分析。
  • 中位随访3.7年,主要终点为MACE(心血管死亡、心肌梗死和卒中的复合终点)。

主要发现

  • 随访期间1459例(10.0%)发生MACE。
  • 连续变量模型中,IL-6升高与MACE风险独立相关(P < .001),且在所有CKD分层中一致。
  • 正常肾功能组:IL-6≥2.0 vs <2.0 ng/L的MACE年发生率2.9% vs 1.9%(HR 1.35;95%CI 1.02-1.78)。
  • 轻度CKD组:3.3% vs 1.9%(HR 1.57;95%CI 1.35-1.83)。
  • 中重度CKD组:5.0% vs 2.9%(HR 1.60;95%CI 1.28-1.99)。

关键数值与推荐

  • IL-6界值:<2.0 ng/L vs ≥2.0 ng/L。
  • eGFR分层:正常≥90 mL/min/1.73 m2;轻度下降60-90 mL/min/1.73 m2;中重度下降<60 mL/min/1.73 m2。
  • MACE定义:心血管死亡、心肌梗死和卒中的复合终点。

临床怎么用

  • 对慢性冠脉综合征患者,可检测IL-6并结合eGFR分层评估MACE风险。
  • IL-6≥2.0 ng/L且合并CKD的患者可能从抗炎治疗中获益,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Inflammation promotes cardiovascular disease and anti-inflammatory treatment reduces cardiovascular events in patients with chronic coronary syndrome. Chronic kidney disease (CKD) is a risk factor for cardiovascular disease. It is unclear how inflammation mediated by interleukin 6 (IL-6) in patients with CKD is linked to cardiovascular disease. OBJECTIVE: To investigate associations between IL-6 and cardiovascular outcomes in patients with chronic coronary syndrome in association with kidney function. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study included patients enrolled at 663 centers in 39 countries with chronic coronary syndrome who were included in the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy (STABILITY) trial. Patients were enrolled between December 2008 and April 2010 and were followed up for a median length of 3.7 years. Analysis in this substudy began September 2020. EXPOSURES: Exposures were IL-6 and creatinine estimated glomerular filtration rates (eGFR), which were collected at baseline. Associations between continuous and categorical levels (<2.0 ng/L vs ≥2.0 ng/L) of IL-6 and cardiovascular outcomes were tested in association with eGFR cutoffs (normal eGFR level [≥90 mL/min/1.73 m2], mildly decreased eGFR level [60-90 mL/min/1.73 m2], and moderately to severely decreased eGFR level [<60 mL/min/1.73 m2]). MAIN OUTCOMES AND MEASURES: Main outcome was major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction, and stroke. RESULTS: This substudy of the STABILITY trial included 14 611 patients with available IL-6 levels at baseline. The median (interquartile range) age was 65 (59-71) years, and 2700 (18.5%) were female. During follow-up, MACE occurred in 1459 individuals (10.0%). Higher levels of IL-6 were in continuous models independently associated with risk of MACE (P < .001) in all CKD strata. Using predefined strata, elevated IL-6 level (≥2.0 vs <2.0 ng/L) was associated with increased risk of MACE at normal kidney function (2.9% vs 1.9% events/y [hazard ratio, 1.35; 95% CI, 1.02-1.78]), mild CKD (3.3% vs 1.9% [hazard ratio, 1.57; 95% CI, 1.35-1.83]), and moderate to severe CKD (5.0% vs 2.9% [hazard ratio, 1.60; 95% CI, 1.28-1.99]). CONCLUSIONS AND RELEVANCE: In patients with chronic coronary syndrome, elevated levels of IL-6 were associated with risk of MACE in all CKD strata. Thus, IL-6 and CKD stage may help when identifying patients with chronic coronary syndrome for anti-inflammatory treatment.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Batra G, Ghukasyan Lakic T, Lindbäck J, et al. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. JAMA Cardiol. 2021. PMID: 34431970. doi:10.1001/jamacardio.2021.3079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。